Paratek Pharmaceuticals Inc (NASDAQ:PRTK)’s share price dropped 6.3% during trading on Monday . The company traded as low as $5.84 and last traded at $5.92. Approximately 535,111 shares traded hands during mid-day trading, an increase of 77% from the average daily volume of 301,682 shares. The stock had previously closed at $6.32.
PRTK has been the subject of a number of research reports. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 27th. ValuEngine downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 2nd. LADENBURG THALM/SH SH reissued a “buy” rating and set a $18.00 price target on shares of Paratek Pharmaceuticals in a report on Tuesday, December 18th. Wedbush reissued an “outperform” rating on shares of Paratek Pharmaceuticals in a report on Wednesday, March 6th. Finally, Canaccord Genuity set a $25.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Monday, March 18th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $23.25.
The firm has a market cap of $202.63 million, a PE ratio of -1.66 and a beta of 1.52. The company has a debt-to-equity ratio of 4.81, a quick ratio of 14.41 and a current ratio of 14.41.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.06). Paratek Pharmaceuticals had a negative net margin of 656.41% and a negative return on equity of 149.09%. The firm had revenue of $17.02 million for the quarter, compared to analyst estimates of $16.50 million. On average, research analysts anticipate that Paratek Pharmaceuticals Inc will post -4.38 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in PRTK. JPMorgan Chase & Co. boosted its holdings in shares of Paratek Pharmaceuticals by 6.5% during the third quarter. JPMorgan Chase & Co. now owns 337,110 shares of the specialty pharmaceutical company’s stock valued at $3,271,000 after acquiring an additional 20,476 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Paratek Pharmaceuticals by 5.7% during the third quarter. Bank of New York Mellon Corp now owns 136,376 shares of the specialty pharmaceutical company’s stock valued at $1,323,000 after purchasing an additional 7,332 shares in the last quarter. BlackRock Inc. raised its stake in shares of Paratek Pharmaceuticals by 3.6% during the third quarter. BlackRock Inc. now owns 2,677,154 shares of the specialty pharmaceutical company’s stock valued at $25,967,000 after purchasing an additional 93,764 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Paratek Pharmaceuticals during the third quarter valued at about $1,860,000. Finally, MetLife Investment Advisors LLC raised its stake in shares of Paratek Pharmaceuticals by 75.5% during the third quarter. MetLife Investment Advisors LLC now owns 28,473 shares of the specialty pharmaceutical company’s stock valued at $276,000 after purchasing an additional 12,251 shares in the last quarter. 74.30% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Paratek Pharmaceuticals (PRTK) Shares Down 6.3%” was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://transcriptdaily.com/2019/04/16/paratek-pharmaceuticals-prtk-shares-down-6-3.html.
About Paratek Pharmaceuticals (NASDAQ:PRTK)
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Featured Story: How to Trade Using Analysts Ratings
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.